CARMA FUND I Completes First Closing of € 47 m to Accelerate the Transfer of...
A consortium of strong partners has launched the CARMA FUND I as a new vehicle for the translation of promising early-stage life-science projects: the initiators, Ascenion GmbH, a life-science focused...
View ArticleEvotec SE reports results of annual general meeting 2022
Evotec SE today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s virtual Annual General Meeting 2022 with the required majority.
View ArticleEvotec SE: translational BRIDGE partnership beLAB2122 selects oncology...
Evotec SE announced today that a project has been selected for further development within beLAB2122, a translational BRIDGE collaboration between Evotec and Bristol Myers Squibb. beLAB2122 aims to...
View ArticleEvotec completes acquisition of Rigenerand
Evotec SE today announced that the strategic transaction to acquire Rigenerand Srl, signed in May 2022, has been completed. Based out of Medolla, Italy, the cell technology company with leading edge in...
View ArticleEvotec, Boehringer Ingelheim, and bioMérieux launch Aurobac, a joint venture...
Evotec SE, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and bioMérieux, a world leader in in vitro diagnostics, announced today that they have formed a joint venture to...
View ArticleEvotec's translational BRIDGE beLAB1407 awards project from Dundee University
Evotec SE announced today that after a successful call for proposals, University of Dundee has been awarded its first funding within the beLAB1407 BRIDGE initiative. beLAB1407 is a translational BRIDGE...
View ArticleEvotec SE reports first half-year 2022 results on 11 August 2022
Evotec SE will announce its financial results for the first half-year 2022 on Thursday, 11 August 2022. The Company is going to hold a conference call to discuss the results as well as to provide an...
View ArticleJust – Evotec Biologics and Alpine Immune Sciences expand partnership for...
Evotec SE and Alpine Immune Sciences today announced that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., expanded a multi-year partnership with Alpine for the development of a...
View ArticleEvotec SE reports results for the first half-year 2022 and provides corporate...
Evotec SE today announced its financial results for the first half-year of 2022.
View ArticlePAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to...
The Project to Accelerate New Treatments for Tuberculosis collaboration announced today the execution of a joint development agreement supporting the progression of two investigational tuberculosis...
View ArticleEvotec expands clinical and commercial drug substance manufacturing with...
Evotec SE announced today that the Company expands its clinical and commercial manufacturing platform for small molecule therapeutics by acquiring Central Glass Germany GmbH from the Japanese chemical...
View ArticleEvotec wins R&D 100 Award for EVOpanHunter
Evotec announces that the Company has been selected as a winner of the 2022 R&D 100 Award in the following category: Software and Services for their multi-omics analysis platform EVOpanHunter.
View ArticleEvotec wins R&D 100 Award for PanHunter
Evotec announces that the Company has been selected as a winner of the 2022 R&D 100 Award in the following category: Software and Services for their multi-omics analysis platform PanHunter.
View ArticleEvotec initiates ground-breaking for new biologics facility J.POD® Toulouse,...
Evotec SE today officially launched the construction of its J.POD® biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France. J.POD® Toulouse, France (EU), the second facility of...
View ArticleJust – Evotec Biologics awarded contract from U.S. Department of Defense...
Evotec SE today announced that the U.S. Department of Defense (“DOD”) has awarded Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc. a contract valued up to $ 49.9 m for the rapid...
View ArticleAurobac Therapeutics Appoints Florence Séjourné as Chief Executive Officer
Aurobac Therapeutics SAS (Aurobac), announced today the appointment of Florence Séjourné as Chief Executive Officer. Aurobac is a joint venture recently created by Boehringer Ingelheim, Evotec SE and...
View ArticleEvotec and TIAP expand LAB150 BRIDGE partnership to include Amgen
Evotec SE and Toronto Innovation Acceleration Partners (“TIAP”) today announced that the two companies have expanded LAB150, their translational BRIDGE partnership, to include Amgen as a strategic...
View ArticleEvotec launches PanOmics data analysis platform PanHunter at Bio-IT World
Evotec SE today announced the launch of the first commercial version of its PanOmics data analysis platform PanHunter at Bio-IT World (18-19 October in Berlin, Germany). PanHunter is Evotec’s PanOmics...
View ArticleEvotec enters partnership with Hannover Medical School to create molecular...
Evotec SE announced today that the Company has entered a partnership with Hannover Medical School (“MHH”), one of the leading German universities, to generate a molecular patient database for Sjögren’s...
View ArticleEvotec, CDP Venture Capital and Angelini Ventures launch translational...
Evotec SE today announced the launch of “Extend”, a translational BRIDGE partnership in cooperation with CDP Venture Capital Sgr, a strategic pillar to Italy's economic growth and innovation, and...
View Article